ANI Retained Earnings from 2010 to 2024

ANIP Stock

USD 59.39 1.53 2.64%

ANI Pharmaceuticals Retained Earnings yearly trend continues to be relatively stable with very little volatility. Retained Earnings are likely to drop to about -84.1 M. Retained Earnings is the cumulative amount of net income that ANI Pharmaceuticals retains for reinvestment in its operations, rather than distributing it to shareholders as dividends. View All Fundamentals

Retained Earnings

First Reported

2000-03-31

Previous Quarter

-65 M

Current Value

-89.6 M

Quarterly Volatility

65.2 M

Dot-com Bubble

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Check ANI Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among ANI Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 62.8 M, Interest Expense of 28.3 M or Selling General Administrative of 157.9 M, as well as many indicators such as Price To Sales Ratio of 1.94, Dividend Yield of 0.0012 or PTB Ratio of 2.18. ANI financial statements analysis is a perfect complement when working with ANI Pharmaceuticals Valuation or Volatility modules.

Check out the analysis of ANI Pharmaceuticals Correlation against competitors.

To learn how to invest in ANI Stock, please use our How to Invest in ANI Pharmaceuticals guide.

Latest ANI Pharmaceuticals' Retained Earnings Growth Pattern

Below is the plot of the Retained Earnings of ANI Pharmaceuticals over the last few years. It is the cumulative amount of net income that a company retains for reinvestment in its operations, rather than distributing it to shareholders as dividends. ANI Pharmaceuticals' Retained Earnings historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in ANI Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.

View

Last Reported (80.13 M)

10 Years Trend

Pretty Stable

Compare to Others All Fundamentals

Retained Earnings

Timeline

ANI Retained Earnings Regression Statistics

	Arithmetic Mean	(55,845,524)
	Coefficient Of Variation	(142.79)
	Mean Deviation	59,270,002
	Median	(19,725,000)
	Standard Deviation	79,743,752
	Sample Variance	6359.1T
	Range	262.5M
	R-Value	0.23
	Mean Square Error	6483T
	R-Squared	0.05
	Significance	0.41
	Slope	4,117,713
	Total Sum of Squares	89026.9T

ANI Retained Earnings History

	2024	-84.1 M
	2023	-80.1 M
	2022	-97.3 M
	2021	-47.8 M
	2020	-5 M
	2019	17.6 M
	2018	11.5 M

Other Fundumenentals of ANI Pharmaceuticals

Retained Earnings Total Equity

ANI Pharmaceuticals Retained Earnings component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Total Liab	Total Current Assets	Common Stock	Short Term Debt	Current Deferred Revenue	Net Receivables	Net Tangible Assets	Long Term Debt	Good Will	Long Term Debt Total	Long Term Investments	Treasury Stock	Intangible Assets	Property Plant Equipment	Capital Surpluse	Short Long Term Debt	Net Invested Capital	Net Working Capital	Capital Stock	Accumulated Depreciation
Total Assets		1.0	0.59	0.16	0.94	0.99	0.95	-0.48	-0.18	0.61	0.97	0.09	0.87	0.9	0.67	0.65	-0.81	0.81	0.92	0.88	-0.8	0.83	0.8	0.81	-0.73
Total Stockholder Equity	1.0		0.52	0.15	0.94	0.98	0.96	-0.48	-0.14	0.64	0.95	0.15	0.86	0.91	0.66	0.68	-0.77	0.77	0.9	0.88	-0.76	0.84	0.82	0.81	-0.73
Net Debt	0.59	0.52		0.34	0.44	0.66	0.3	-0.44	-0.21	0.06	0.65	-0.5	0.68	0.39	0.57	-0.06	-0.78	0.9	0.72	0.61	-0.68	0.38	0.16	0.45	-0.29
Retained Earnings	0.16	0.15	0.34		-0.06	0.18	0.04	-0.89	0.4	0.08	0.09	-0.18	0.24	-0.11	0.2	-0.12	-0.24	0.39	0.24	0.09	-0.1	-0.14	-0.2	-0.16	0.21
Accounts Payable	0.94	0.94	0.44	-0.06		0.92	0.94	-0.31	-0.38	0.56	0.96	0.22	0.77	0.96	0.58	0.75	-0.77	0.62	0.87	0.84	-0.77	0.9	0.91	0.86	-0.85
Total Liab	0.99	0.98	0.66	0.18	0.92		0.91	-0.48	-0.21	0.56	0.97	0.04	0.89	0.88	0.68	0.58	-0.85	0.85	0.94	0.89	-0.83	0.82	0.76	0.8	-0.71
Total Current Assets	0.95	0.96	0.3	0.04	0.94	0.91		-0.39	-0.16	0.71	0.9	0.34	0.78	0.92	0.58	0.79	-0.66	0.59	0.8	0.82	-0.7	0.85	0.89	0.79	-0.79
Common Stock	-0.48	-0.48	-0.44	-0.89	-0.31	-0.48	-0.39		-0.22	-0.37	-0.43	0.01	-0.5	-0.3	-0.42	-0.16	0.42	-0.54	-0.47	-0.42	0.35	-0.24	-0.2	-0.24	0.2
Short Term Debt	-0.18	-0.14	-0.21	0.4	-0.38	-0.21	-0.16	-0.22		0.14	-0.33	0.13	-0.17	-0.37	-0.19	-0.24	0.31	-0.07	-0.27	-0.22	0.61	-0.39	-0.47	-0.39	0.32
Current Deferred Revenue	0.61	0.64	0.06	0.08	0.56	0.56	0.71	-0.37	0.14		0.55	0.28	0.49	0.58	0.34	0.62	-0.11	0.31	0.29	0.5	-0.34	0.5	0.64	0.46	-0.72
Net Receivables	0.97	0.95	0.65	0.09	0.96	0.97	0.9	-0.43	-0.33	0.55		0.06	0.85	0.92	0.66	0.63	-0.84	0.78	0.93	0.89	-0.83	0.86	0.82	0.84	-0.8
Net Tangible Assets	0.09	0.15	-0.5	-0.18	0.22	0.04	0.34	0.01	0.13	0.28	0.06		0.14	0.28	0.03	0.22	0.12	-0.34	-0.06	0.16	0.13	0.28	0.35	0.28	-0.31
Long Term Debt	0.87	0.86	0.68	0.24	0.77	0.89	0.78	-0.5	-0.17	0.49	0.85	0.14		0.77	0.81	0.41	-0.75	0.84	0.82	0.95	-0.79	0.81	0.65	0.82	-0.57
Good Will	0.9	0.91	0.39	-0.11	0.96	0.88	0.92	-0.3	-0.37	0.58	0.92	0.28	0.77		0.54	0.7	-0.66	0.59	0.79	0.86	-0.71	0.95	0.93	0.94	-0.83
Long Term Debt Total	0.67	0.66	0.57	0.2	0.58	0.68	0.58	-0.42	-0.19	0.34	0.66	0.03	0.81	0.54		0.34	-0.64	0.68	0.67	0.74	-0.72	0.59	0.49	0.57	-0.38
Long Term Investments	0.65	0.68	-0.06	-0.12	0.75	0.58	0.79	-0.16	-0.24	0.62	0.63	0.22	0.41	0.7	0.34		-0.35	0.22	0.5	0.55	-0.44	0.71	0.82	0.56	-0.64
Treasury Stock	-0.81	-0.77	-0.78	-0.24	-0.77	-0.85	-0.66	0.42	0.31	-0.11	-0.84	0.12	-0.75	-0.66	-0.64	-0.35		-0.81	-0.96	-0.74	0.8	-0.62	-0.48	-0.61	0.49
Intangible Assets	0.81	0.77	0.9	0.39	0.62	0.85	0.59	-0.54	-0.07	0.31	0.78	-0.34	0.84	0.59	0.68	0.22	-0.81		0.85	0.79	-0.74	0.58	0.38	0.61	-0.37
Property Plant Equipment	0.92	0.9	0.72	0.24	0.87	0.94	0.8	-0.47	-0.27	0.29	0.93	-0.06	0.82	0.79	0.67	0.5	-0.96	0.85		0.82	-0.82	0.73	0.63	0.7	-0.56
Capital Surpluse	0.88	0.88	0.61	0.09	0.84	0.89	0.82	-0.42	-0.22	0.5	0.89	0.16	0.95	0.86	0.74	0.55	-0.74	0.79	0.82		-0.73	0.93	0.72	0.92	-0.67
Short Long Term Debt	-0.8	-0.76	-0.68	-0.1	-0.77	-0.83	-0.7	0.35	0.61	-0.34	-0.83	0.13	-0.79	-0.71	-0.72	-0.44	0.8	-0.74	-0.82	-0.73		-0.67	-0.68	-0.66	0.56
Net Invested Capital	0.83	0.84	0.38	-0.14	0.9	0.82	0.85	-0.24	-0.39	0.5	0.86	0.28	0.81	0.95	0.59	0.71	-0.62	0.58	0.73	0.93	-0.67		0.88	0.98	-0.75
Net Working Capital	0.8	0.82	0.16	-0.2	0.91	0.76	0.89	-0.2	-0.47	0.64	0.82	0.35	0.65	0.93	0.49	0.82	-0.48	0.38	0.63	0.72	-0.68	0.88		0.82	-0.81
Capital Stock	0.81	0.81	0.45	-0.16	0.86	0.8	0.79	-0.24	-0.39	0.46	0.84	0.28	0.82	0.94	0.57	0.56	-0.61	0.61	0.7	0.92	-0.66	0.98	0.82		-0.75
Accumulated Depreciation	-0.73	-0.73	-0.29	0.21	-0.85	-0.71	-0.79	0.2	0.32	-0.72	-0.8	-0.31	-0.57	-0.83	-0.38	-0.64	0.49	-0.37	-0.56	-0.67	0.56	-0.75	-0.81	-0.75

Click cells to compare fundamentals

About ANI Pharmaceuticals Financial Statements

ANI Pharmaceuticals shareholders use historical fundamental indicators, such as Retained Earnings, to determine how well the company is positioned to perform in the future. Although ANI Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. The changes in ANI Pharmaceuticals' assets and liabilities, for example, are also reflected in the revenues and expenses on on ANI Pharmaceuticals' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.

	Last Reported	Projected for Next Year
Retained Earnings	-80.1 M	-84.1 M
Retained Earnings Total Equity	-111.9 M	-117.5 M

Pair Trading with ANI Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if ANI Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ANI Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

The ability to find closely correlated positions to ANI Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace ANI Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back ANI Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling ANI Pharmaceuticals to buy it.

The correlation of ANI Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as ANI Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if ANI Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for ANI Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Additional Tools for ANI Stock Analysis

When running ANI Pharmaceuticals' price analysis, check to measure ANI Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ANI Pharmaceuticals is operating at the current time. Most of ANI Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of ANI Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ANI Pharmaceuticals' price. Additionally, you may evaluate how the addition of ANI Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC